Dyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co. to "Neutral"

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was downgraded by equities research analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating in a report issued on Thursday, MarketBeat.com reports. They presently have a $35.00 target price on the stock, down from their prior target price of $43.00. JPMorgan Chase & Co.'s price objective indicates a potential upside of 12.54% from the stock's previous close.

DYN has been the subject of a number of other reports. Oppenheimer reaffirmed an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Morgan Stanley increased their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Finally, Piper Sandler reissued an "overweight" rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $50.60.

Dyne Therapeutics Trading Down 3.9 %

Shares of DYN traded down $1.26 during trading hours on Thursday, reaching $31.10. 972,334 shares of the company traded hands, compared to its average volume of 1,523,443. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -7.83 and a beta of 1.05. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $47.45. The stock's fifty day moving average price is $36.63 and its 200 day moving average price is $34.63.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, research analysts forecast that Dyne Therapeutics will post -2.96 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Dirk Kersten sold 23,671 shares of the company's stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the transaction, the director now directly owns 99,652 shares of the company's stock, valued at $3,522,698.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the completion of the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John Cox bought 32,000 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. This trade represents a -100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DYN. RA Capital Management L.P. purchased a new position in shares of Dyne Therapeutics during the first quarter worth $140,666,000. Vanguard Group Inc. raised its stake in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company's stock valued at $97,669,000 after buying an additional 1,110,629 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Dyne Therapeutics by 23,512.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company's stock valued at $75,915,000 after buying an additional 2,663,910 shares during the period. Artal Group S.A. boosted its stake in shares of Dyne Therapeutics by 24.6% in the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company's stock worth $43,095,000 after buying an additional 300,000 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Dyne Therapeutics by 10.4% in the second quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company's stock worth $42,881,000 after buying an additional 114,888 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.